Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825694 | 0.88 | ALDH1A1 (0.47) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL5918013 | 0.86 | ALDH1A1 (0.46) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL5918020 | 0.86 | ALDH1A1 (0.46) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL5918017 | 0.86 | ALDH1A1 (0.46) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL8671709 | 0.81 | ALDH1A1 (0.50) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL3630260 | 0.81 | TAAR1 (0.43) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL27628750 | 0.79 | SMN1; SMN2 (0.49) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL955333 | 0.78 | ALDH1A1 (0.49) | ALDH1A1ALOX15TAAR1USP2NPSR1 | |
| SCHEMBL27628838 | 0.78 | — | — | |
| SCHEMBL826560 | 0.77 | ALDH1A1 (0.41) | ALDH1A1ALOX15TAAR1USP2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234253-B2 | Silicone compounds with a substituted amine group and a benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2025-02-25 | — | — | US | claimed |
| US-20250051370-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2025-02-13 | — | — | US | claimed |
| US-20220064191-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2022-03-03 | — | — | US | claimed |
| EP-3218425-B1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2020-05-13 | — | — | EP | claimed |
| US-10561168-B2 | Tobacco-derived components and materials | R.J. REYNOLDS TOBACCO COMPANY (US) | 2020-02-18 | — | — | US | claimed |
| US-20180027867-A1 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | REYNOLDS TOBACCO CO R (US) | 2018-02-01 | — | — | US | claimed |
| WO-2017196762-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2017-11-16 | — | — | WO | claimed |
| US-20170327647-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2017-11-16 | — | — | US | claimed |
| EP-3218425-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2017-09-20 | — | — | EP | claimed |
| WO-2016077513-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-19 | — | — | WO | claimed |
| US-20160137674-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2016-05-19 | — | — | US | claimed |
| EP-2523568-B1 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | REYNOLDS TOBACCO CO R (US) | 2013-12-18 | — | — | EP | claimed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20130014771-A1 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | R. J. REYNOLDS TOBACCO COMPANY | 2013-01-17 | — | — | US | claimed |
| EP-2523568-A2 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | R. J. Reynolds Tobacco Company (US) | 2012-11-21 | — | — | EP | claimed |
| WO-2011088171-A2 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | R. J. REYNOLDS TOBACCO COMPANY (US) | 2011-07-21 | — | — | WO | claimed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | claimed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | claimed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | claimed |
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | PROCTER & GAMBLE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3094193-B1 | PROCESS FOR PRODUCING FLAVORANTS AND RELATED MATERIALS | REYNOLDS TOBACCO CO R (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12234253-B2 | Silicone compounds with a substituted amine group and a benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250051370-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2025-02-13 | — | — | US | disclosed |
| US-12037320-B2 | Pro-benefit-agent compounds with heterocyclic moieties | THE PROCTER & GAMBLE COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| US-20230220304-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID DIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| US-20230002330-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2023-01-05 | — | — | US | disclosed |
| US-20220403297-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH CARBON/NITROGEN BONDS | THE PROCTER & GAMBLE COMPANY | 2022-12-22 | — | — | US | disclosed |
| US-20220177813-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2022-06-09 | — | — | US | disclosed |
| US-20220064191-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2022-03-03 | — | — | US | disclosed |
| US-11192904-B2 | Silicone compounds comprising a benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| CN-106255424-B | Process for producing fragrances and related materials | R.J.雷诺兹烟草公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3218425-B1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20200095267-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2020-03-26 | — | — | US | disclosed |
| US-10590148-B2 | Silicone compounds comprising a ketone or aldehyde benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2020-03-17 | — | — | US | disclosed |
| US-10561168-B2 | Tobacco-derived components and materials | R.J. REYNOLDS TOBACCO COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3572449-A1 | SILICONE COMPOUNDS | The Procter & Gamble Company (US) | 2019-11-27 | — | — | EP | disclosed |
| US-10188137-B2 | Process for producing flavorants and related materials | R.J. REYNOLDS TOBACCO COMPANY (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2111444-B1 | BENEFIT AGENT DELIVERY COMPOSITIONS | PROCTER & GAMBLE (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180027867-A1 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | REYNOLDS TOBACCO CO R (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2017196762-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327647-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2017-11-16 | — | — | US | disclosed |
| EP-3218425-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3094193-A1 | PROCESS FOR PRODUCING FLAVORANTS AND RELATED MATERIALS | R. J. Reynolds Tobacco Company (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2358689-B9 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160213056-A1 | PROCESS FOR PRODUCING FLAVORANTS AND RELATED MATERIALS | R.J. REYNOLDS TOBACCO COMPANY | 2016-07-28 | — | — | US | disclosed |
| WO-2016077513-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137674-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2016-05-19 | — | — | US | disclosed |
| US-9265284-B2 | Process for producing flavorants and related materials | R.J. REYNOLDS TOBACCO COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2358689-B1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150201669-A1 | PROCESS FOR PRODUCING FLAVORANTS AND RELATED MATERIALS | R. J. REYNOLDS TOBACCO COMPANY | 2015-07-23 | — | — | US | disclosed |
| WO-2015109085-A1 | PROCESS FOR PRODUCING FLAVORANTS AND RELATED MATERIALS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2015-07-23 | — | — | WO | disclosed |
| US-8955523-B2 | Tobacco-derived components and materials | R.J. REYNOLDS TOBACCO COMPANY (US) | 2015-02-17 | — | — | US | disclosed |
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8697874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2523568-B1 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | REYNOLDS TOBACCO CO R (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8450259-B2 | Benefit agent delivery compositions | THE PROCTER & GAMBLE COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20130014771-A1 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | R. J. REYNOLDS TOBACCO COMPANY | 2013-01-17 | — | — | US | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8324395-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-2523568-A2 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | R. J. Reynolds Tobacco Company (US) | 2012-11-21 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8273741-B2 | Imidazo-pyridazinyl compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-2399921-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-8044049-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8034812-B2 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2358689-A1 | Benzothiazole derivatives as anticancer agents | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20110174323-A1 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | R.J. REYNOLDS TOBACCO COMPANY | 2011-07-21 | — | — | US | disclosed |
| WO-2011088171-A2 | TOBACCO-DERIVED COMPONENTS AND MATERIALS | R. J. REYNOLDS TOBACCO COMPANY (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100331190-A1 | BENEFIT AGENT DELIVERY COMPOSITIONS | SMETS JOHAN | 2010-12-30 | — | — | US | disclosed |
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| WO-2010064722-A1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | WO | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2181987-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20100087357-A1 | PERFUME SYSTEMS | MORGAN III GEORGE KAVIN | 2010-04-08 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2162445-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
| US-20090233836-A1 | Perfuming method and product | THE PROCTER & GAMBLE COMPANY (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2049541-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048351-A1 | Benefit agent delivery compositions | SMETS JOHAN | 2009-02-19 | — | — | US | disclosed |
| WO-2008150015-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | WO | disclosed |
| US-20080200363-A1 | Perfumes, brighteners, insect repellants, flavors, vitamins, fabric softeners, skin care agents; increasing potency, reducing cost | PROECTER & GAMBLE COMPANY, THE | 2008-08-21 | — | — | US | disclosed |
| US-20080200359-A1 | Improved deposition and retention; employing polymer and crosslinking agent; perfumes, brighteners, insect repellants, silicones, waxes, flavors, vitamins, fabric softeners, skin care agents | PROCTER & GAMBLE COMPANY, THE | 2008-08-21 | — | — | US | disclosed |
| US-20080194454-A1 | Perfume systems | PROCTER & GAMBLE COMPANY, THE | 2008-08-14 | — | — | US | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | ALDH1A1 182/4885ALOX15 2826/4885TAAR1 3196/4885 |
| US-20160137674-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | ALDH1A1 3917/4885ALOX15 2271/4885TAAR1 1199/4885 |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | ALDH1A1 1105/4885ALOX15 1229/4885TAAR1 1854/4885 |
| US-20200095267-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | ALDH1A1 3917/4885ALOX15 2271/4885TAAR1 1199/4885 |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | ALDH1A1 809/4885ALOX15 3978/4885TAAR1 497/4885 |
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | ALDH1A1 1157/4885ALOX15 3141/4885TAAR1 3128/4885 |
| US-20250051370-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | ALDH1A1 3917/4885ALOX15 2271/4885TAAR1 1199/4885 |
| US-12037320-B2 | Pro-benefit-agent compounds with heterocyclic moieties | PLG, PAM, PREP | ALDH1A1 151/4885ALOX15 226/4885TAAR1 1305/4885 |
| US-10590148-B2 | Silicone compounds comprising a ketone or aldehyde benefit agent moiety | SMN1; SMN2, KARS1, ACADM | ALDH1A1 42/4885ALOX15 1810/4885TAAR1 422/4885 |
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | ALDH1A1 788/4885ALOX15 448/4885TAAR1 890/4885 |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | ALDH1A1 625/4885ALOX15 2253/4885TAAR1 2905/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | ALDH1A1 182/4885ALOX15 2826/4885TAAR1 3196/4885 |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | HGFAC, PROKR1, FABP2 | ALDH1A1 544/4885ALOX15 986/4885TAAR1 2216/4885 |
| US-12234253-B2 | Silicone compounds with a substituted amine group and a benefit agent moiety | SMS, SRM, AAAS | ALDH1A1 3361/4885ALOX15 2826/4885TAAR1 59/4885 |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | ARGLU1, DAO, PNISR | ALDH1A1 4253/4885ALOX15 263/4885TAAR1 422/4885 |
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | F2, C9, S100A8 | ALDH1A1 2233/4885ALOX15 2173/4885TAAR1 3417/4885 |
| US-20230002330-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | PLG, PAM, PREP | ALDH1A1 151/4885ALOX15 226/4885TAAR1 1305/4885 |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NR3C2, RAF1 | ALDH1A1 1374/4885ALOX15 2771/4885TAAR1 604/4885 |
| US-20100087357-A1 | PERFUME SYSTEMS | TRPA1, SPNS2, PAPSS1 | ALDH1A1 836/4885ALOX15 879/4885TAAR1 331/4885 |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | ALDH1A1 1236/4885ALOX15 3940/4885TAAR1 3386/4885 |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | ALDH1A1 182/4885ALOX15 2826/4885TAAR1 3196/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | ALDH1A1 1687/4885ALOX15 4056/4885TAAR1 3370/4885 |
| US-11192904-B2 | Silicone compounds comprising a benefit agent moiety | SMCHD1, SMN1; SMN2, SGMS2 | ALDH1A1 4146/4885ALOX15 2841/4885TAAR1 946/4885 |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | ALDH1A1 324/4885ALOX15 320/4885TAAR1 460/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | ALDH1A1 816/4885ALOX15 3959/4885TAAR1 473/4885 |
| US-20080194454-A1 | Perfume systems | TRPA1, SPNS2, PAPSS1 | ALDH1A1 836/4885ALOX15 879/4885TAAR1 331/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | ALDH1A1 728/4885ALOX15 423/4885TAAR1 3204/4885 |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | BCAT2, MTR, ASNS | ALDH1A1 3811/4885ALOX15 639/4885TAAR1 3855/4885 |
| US-20220064191-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | ALDH1A1 3917/4885ALOX15 2271/4885TAAR1 1199/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | ALDH1A1 1236/4885ALOX15 3940/4885TAAR1 3386/4885 |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | ALDH1A1 2812/4885ALOX15 2802/4885TAAR1 890/4885 |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | ALDH1A1 208/4885ALOX15 3236/4885TAAR1 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.